In patients with c-Met protein–overexpressing non-squamous NSCLC, MET was amplified in 18% of samples tested (n = 9/49; c-Met high, 21% [6/28]; c-Met intermediate, 14% [3/21]). This evidence concerns the gene MET and non-small cell lung carcinoma.